GLOW is three peptides — GHK-Cu, BPC-157 and TB-500. KLOW is those three plus KPV, the anti-inflammatory tripeptide, at a higher total. Neither blend has been studied as a blend; the research belongs to the four components separately.
| KLOW Stack from $190 | GLOW Stack from $170 | |
|---|---|---|
| Contains | KPV, GHK-Cu, TB-500, BPC-157 | GHK-Cu, BPC-157, TB-500 |
| Total peptide | 80MG | 70MG |
| Extra component | KPV, anti-inflammatory | — |
| Research focus | Skin, soft tissue, inflammation | Skin and soft tissue |
| Studied as a blend | No | No |
| WADA status | Two components prohibited | Two components prohibited |
Both are prepared by weight in our own lab and tested as finished products rather than assembled from separately certified inputs. The question between them is whether the fourth component earns its place.
KPV is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity through NF-κB signalling rather than through a surface receptor. GLOW covers structure and repair; KLOW adds the inflammation arm.
GHK-Cu is the copper carrier, tied to the crosslinking enzymes that build collagen and elastin. TB-500 is associated with actin dynamics and cell migration, BPC-157 with angiogenesis and growth-factor signalling. KPV is the one KLOW adds: reported to act intracellularly, reducing NF-κB activation and the inflammatory cytokines that follow.
Read the four compound guides rather than treating either stack as a studied entity. The evidence is theirs, not the blend's.
A four-component blend has four chances to get the ratio wrong, so the finished product is what gets tested: each peptide confirmed by mass spectrometry, purity by HPLC, and contaminant metals screened separately from the copper that belongs in GHK-Cu.
KPV is the last three amino acids of alpha-MSH — lysine, proline, valine — synthesised on their own. Alpha-MSH carries two quite separate activities: pigmentation, which the melanotan compounds act on, and anti-inflammatory activity. They sit in different parts of the molecule, and KPV is the anti-inflammatory end, which is why it produces no pigmentation effect.
Its reported mechanism is unusual for a peptide this small. Published work in intestinal epithelial and immune cells describes KPV entering cells through the PepT1 transporter and reducing NF-κB activation, lowering the inflammatory cytokines that follow — an intracellular route rather than a surface receptor. The most-cited work is in mouse colitis models, with further research in skin inflammation.
So the choice between the blends is really a question about inflammation. GLOW covers structure and repair; KLOW adds an anti-inflammatory arm to it.
No published study covers either blend. The argument for combining these compounds is mechanistic: they are associated with different parts of the same process, so combining them is a reasonable hypothesis. A reasonable hypothesis is not a result, and anyone who tells you a four-way blend is proven is describing something that does not exist.
What a blend does reliably change is practical. One reconstitution instead of three or four. One ratio, identical in every vial, rather than four weighings by hand. One tested batch rather than four separately certified inputs that were never tested together.
For anyone evaluating the components rather than the convenience, the four compound guides carry the actual evidence — including where it is thin, which for KPV is most of it: human data is essentially absent.
A blend has as many chances to go wrong as it has components. Ours are prepared by weight in our own lab and the finished product is tested, not the inputs — so the ratio on the certificate is the ratio in the vial rather than the ratio we intended.
Each peptide is confirmed by mass spectrometry, purity measured by HPLC, and contaminant metals screened with the copper carried by GHK-Cu accounted for separately. That last detail matters in these two blends specifically: a single heavy-metals figure that does not distinguish complexed copper from lead or mercury is not a meaningful number.
Nothing in either blend is registered in Australia. BPC-157 is listed by WADA under S0 and TB-500 under S2, so both blends are prohibited in competitive sport at all times, in and out of competition.
KLOW is 80MG total peptide and GLOW is 70MG. Both are supplied for in-vitro and laboratory research only, to buyers aged 18 and over.
A blend is quoted as total peptide, so 80MG of KLOW is the sum of its four components and 70MG of GLOW the sum of three. The number that matters for any calculation is therefore the per-component amount, not the headline figure, and it is the reason a blend needs its ratio stated rather than just its size.
Reconstitution follows from that. Adding 2ML of bacteriostatic water to an 80MG blend gives 40MG/ML of total peptide, and each component in the proportion the batch was made to. The reconstitution calculator handles the arithmetic per component, which is more useful than doing it on the total and hoping.
It also explains why comparing a blend to a single peptide on price per milligram is misleading in both directions: the milligrams are not of the same thing.
Four peptides in one vial reconstitute as one, which is the practical advantage, but it also means one handling error affects everything in it. Bacteriostatic water rather than sterile water gives a reconstituted vial weeks under refrigeration instead of days, and the copper component makes light exposure worth avoiding — a solution that loses its blue tint has lost the GHK-Cu complex.
Direct the diluent down the side of the vial and swirl; do not shake. Foaming indicates denatured peptide, and in a blend you cannot tell which component it was.
Both blends are made in Blacktown, NSW, tested as finished product at ≥99% HPLC purity with 0 ppm contaminant metals measured separately from the complexed copper.
If the research question involves inflammation, KLOW is the one with a component addressing it. If it does not, the KPV is paying for something the study will not measure, and GLOW covers the same structural and repair mechanisms for less.
If the question is about any single mechanism — copper and collagen crosslinking, cell migration, angiogenesis — the individual peptide is the better instrument, because a blend cannot tell you which component produced an effect. Blends are for convenience and for combined-mechanism work; they are poor tools for attribution.
Total peptide across all four components. The per-component amount is the figure any calculation needs, which is why a blend has to state its ratio.
No. Blends are for convenience and combined-mechanism work; for attributing an effect to one mechanism the individual peptide is the better instrument.
Bacteriostatic water, directed down the side of the vial, swirled not shaken. Foaming indicates denatured peptide, and in a blend you cannot tell which one.
BPC-157 under WADA S0 and TB-500 under S2, so both blends are prohibited at all times.
No. Alpha-MSH carries pigmentation and anti-inflammatory activity in different parts of the molecule, and KPV is the anti-inflammatory fragment.
Published work describes it entering cells through the PepT1 transporter and reducing NF-κB activation — an intracellular route rather than a surface receptor.
KLOW, at 80MG against GLOW at 70MG. The difference is the KPV component.
Because the ratio is the product. Testing what is in the vial confirms the ratio delivered, not the one intended.
KLOW contains KPV in addition to GHK-Cu, BPC-157 and TB-500, at 80MG total peptide. GLOW is the same three without KPV, at 70MG.
An anti-inflammatory component. KPV is the C-terminal tripeptide of alpha-MSH, reported to reduce NF-κB activation.
Not as a blend. The published research covers each component separately, mostly in preclinical models.
Yes. BPC-157 and TB-500 are both on the WADA Prohibited List, so both blends are.
This comparison summarises published research for educational purposes. It is not medical advice. OzPeptides products are sold for research and laboratory use only, not for human consumption. 18+ only.